or Try an Advanced Search...

    Technical Analysis for ZLAB - Zai Lab Limited

    Grade Last Price % Change Price Change
    C 19.59 -6.04% -1.26
    ZLAB closed down 3.25 percent on Wednesday, May 15, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical ZLAB trend table...
    Date Alert Name Type % Chg
    Upper Bollinger Band Walk Strength -6.04%
    Wide Bands Range Expansion -6.04%
    Overbought Stochastic Strength -6.04%
    Slingshot Bullish Bullish Swing Setup -9.10%
    Calm After Storm Range Contraction -9.10%
    Upper Bollinger Band Walk Strength -9.10%
    Wide Bands Range Expansion -9.10%
    Above Upper BB Strength -9.10%
    Overbought Stochastic Strength -9.10%
    Upper Bollinger Band Touch Strength -9.10%
    Older End-of-Day Signals for ZLAB ...

       Recent Intraday Alerts

    Alert Time
    Down 5% 7 minutes ago
    Down 3% 7 minutes ago
    Fell Below Previous Day's Low 7 minutes ago
    Down 2 % 7 minutes ago
    Down 1% 7 minutes ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ZLAB Chart by TradingView
    Basic chart:

    Profile

    Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases

    Is ZLAB a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
    May 13 BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
    May 13 Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
    May 11 Zai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
    May 10 Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript
    May 9 Zai Lab Limited (ZLAB) Q1 2024 Earnings Call Transcript
    May 9 Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
    May 9 Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
    May 8 Zai Lab GAAP EPADS of -$0.55 beats by $0.39, revenue of $87.15M beats by $11.91M
    May 8 Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
    See more ZLAB news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 37.92
    52 Week Low 13.48
    Average Volume 637,073
    200-Day Moving Average 22.91
    50-Day Moving Average 16.93
    20-Day Moving Average 17.08
    10-Day Moving Average 18.80
    Average True Range 1.14
    RSI (14) 67.85
    ADX 32.5
    +DI 41.99
    -DI 12.67
    Chandelier Exit (Long, 3 ATRs) 18.93
    Chandelier Exit (Short, 3 ATRs) 16.90
    Upper Bollinger Bands 21.86
    Lower Bollinger Band 12.30
    Percent B (%b) 0.89
    BandWidth 56.00
    MACD Line 1.24
    MACD Signal Line 0.56
    MACD Histogram 0.6756
    Fundamentals Value
    Market Cap 2.06 Billion
    Num Shares 98.7 Million
    EPS -3.10
    Price-to-Earnings (P/E) Ratio -6.73
    Price-to-Sales 7.25
    Price-to-Book 2.09
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.26
    Resistance 3 (R3) 22.38 22.04 22.03
    Resistance 2 (R2) 22.04 21.68 21.98 21.95
    Resistance 1 (R1) 21.44 21.46 21.27 21.32 21.87
    Pivot Point 21.10 21.10 21.01 21.04 21.10
    Support 1 (S1) 20.50 20.74 20.33 20.38 19.83
    Support 2 (S2) 20.16 20.52 20.10 19.75
    Support 3 (S3) 19.56 20.16 19.68
    Support 4 (S4) 19.44